The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma

J Manag Care Spec Pharm. 2022 May;28(5):581-583. doi: 10.18553/jmcp.2022.28.5.581.
No abstract available

MeSH terms

  • Anti-Asthmatic Agents* / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma* / drug therapy
  • Biological Therapy
  • Humans

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal, Humanized
  • tezepelumab